Neximmune Inc


Download Data

Neximmune Inc Market Capitalization on May 17, 2024: USD 4.57 M

Neximmune Inc Market Capitalization is USD 4.57 M on May 17, 2024, a -42.10% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Neximmune Inc 52-week high Market Capitalization is USD 18.01 M on February 01, 2024, which is 293.72% above the current Market Capitalization.
  • Neximmune Inc 52-week low Market Capitalization is USD 186.75 K on April 16, 2024, which is -95.92% below the current Market Capitalization.
  • Neximmune Inc average Market Capitalization for the last 52 weeks is USD 6.33 M.

Neximmune Inc

CEO Ms. Kristi Jones R.Ph.
IPO Date Feb. 12, 2021
Location United States
Headquarters 9119 Gaither Road, Gaithersburg, MD, United States, 20877
Employees 6
Sector Healthcare
Industry Biotechnology

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Similar companies


Immix Biopharma Inc

USD 2.47



Xenetic Biosciences Inc

USD 3.61


StockViz Staff

May 20, 2024

Any question? Send us an email